Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease

Kidney International

Volumn 64, Issue 4, 2003, Pages 1381-1388

  Wang, Dan ^a   Iversen, Jens ^b   Wilcox, Christopher S ^b   Strandgaard, Svend ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

Arginine; Chronic renal insufficiency; Hypertension; Nitric oxide; Nitric oxide synthase

Indexed keywords

ACETYLCHOLINE; ARGININE; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE;

ADULT; ARTERY ENDOTHELIUM; ARTERY RESISTANCE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY POLYCYSTIC DISEASE; MALE; PRIORITY JOURNAL; SKIN BLOOD VESSEL; URINARY EXCRETION;

EID: 0141786849     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00236.x     Document Type: Article

References (37)

1. GRIFFIN MD, TORRES VE, GRANDE JP, KUMAR R: Vascular expression of polycystin. J Am Soc Nephrol 8:616-626, 1997
2. WANG D, STRANDGAARD S: The pathogenesis of hypertension in autosomal dominant polycystic kidney disease. J Hypertens 15:925-933, 1997
3. VANHOUTTE P, MOMBOULI J: Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis 39:229-238, 1996
4. DOHI Y, CRISCIONI L, LUSCHER T: Renovascular hypertension impairs formation of endothelium-derived relaxing factors and sensitivity to endothelin-1 in small arteries. Br J Pharmacol 104:349-354, 1991
5. HEYGATE KM, LAWRENCE IG, BENNETT MA, THURSTON H: Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetes rats. Br J Pharmacol 116:3251-3259, 1995
6. HUANG XB, ITO F, NAKAZAWA H, et al: Inducible nitric oxide synthase localization in acquired cystic disease of the kidney. Nephton 81:360-361, 1999
7. MCNALLY PG, WATT PAC, RIMMER T, et al: Impaired contraction and endothelium-dependent relaxation in isolated resistance vessels from patients with insulin dependent diabetes mellitus. Clin Sci 87:31-36, 1994
8. MONCADA S, PALMER R, HIGGS E: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharm Res 43:109-142, 1991
9. SHIMOKAWA H, TAKESHITA A: Endothelial regulation of the cardiovascular system. Intern Med 34:939-946, 1995
10. CHATAIGNEAU T, FELETOU M, HUANG P, et al: Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol 126:219-226, 1999
11. WANG D, IVERSEN J, STRANDGAARD S: Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney rats. J Vasc Res 36:502-509, 1999
12. WANG D, IVERSEN J, STRANDGAARD S: Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:1371-1376, 2000
13. MARTENSSON J, GROTH S, REHLING M, GREF M: Chromium-51-EDTA clearance in adults with a single-plasma sample. J Nucl Med 39:2131-2137, 1998
14. SCHIFFRIN E, DENG L, LAROCHELLE P: Effect of endothelin upon small subcutaneous small arteries of mild essential hypertensive patients. J Hypertens 10:437-444, 1992
15. MULVANY M, HALPERN W: Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41:19-26, 1977
16. AKIBA Y, YAMAGUCHI N, AMANO H, et al: Role of nitric oxide in the control of blood pressure in young and adult spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1:S142-S143, 1995
17. MONCADA S, HIGGS A: Mechanisms of disease: The L-arginine-nitric oxide pathway. N Engl J Med 329:2001-2012, 1993
18. VAZIRI ND, NI Z, OVEISI F: Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension 31:1248-1254, 1998
19. BENVENUTI C, LOISANCE D: Increased serum nitric oxide concentration in cardiac transplantation patients. A marker acute allograft cellular rejection. Transplantation 61:745-749, 1996
20. BOEGER R, BODE-BOEGER S, THIELE W, et al: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Hypertension 95:2068-2074, 1997
21. JESERICH M, SCHINDLER T, OLSCHEWSKI M, et al: Vitamin C improves endothelial function of epicardial coronary arteries in patients with hypercholesterolaemia or essential hypertension. Eur Heart J 20:1676-1680, 1999
22. KUNG CF, LÜSCHER TF: Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 25:194-200, 1995
23. TADDEI S, VIRDIS A, GHIADONI L, SALVETTI A: Endothelial dysfunction in hypertension: fact or fancy? J Cardiovasc Pharmacol 32(Suppl 3):S41-S47, 1998
24. TADDEI S, VIRDIS A, GHIADONI L, et al: Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 29(Pt. 2):274-279, 1997
25. FALLON B, HEAGERTY AM: In vitro perfusion studies of human resistance artery function in essential hypertension. Hypertension 24:16-23, 1999
26. ZEIHER AM, DREXLER H, SAURBIER B, JUST H: Endothelium-mediated coronary blood flow modulation in human. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 92:652-662, 1999
27. DENG L, LI J, SCHIFFRIN EL: Endothelium-dependent relaxation of small arteries from essential hypertension patients: Mechanisms and comparison with normotensive subjects and with response of vessels from spontaneously hypertensive rats. Clin Sci 88:611-622, 1995
28. MATTEI P, VIRDIS A, GHIADONI L, et al: Endothelial function in hypertension. J Nephrol 10:192-197, 1997
29. TADDEI S, VIRDIS A, MATTEI P, et al: Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 94:1298-1303, 1996
30. PANZA QA, QUYYUMI AA, CALLAHAN S, EPSTEIN SE: Effect of anti-hypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 21:1145-1151, 1993
31. MARTENSSON J, GROTH S, REHLING M, GREF M: Chromium-51-EDTA clearance in adults with a single-plasma sample. J Nucl Med 39:2131-2137, 1998
32. KIM K, DRUMMOND I, IBRAGHIMOV-BESKROVNAYA O, et al: Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000
33. XIAO S, WAGNER L, SCHMIDT RJ, BAYLIS C: Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int 59:1466-1472, 2001
34. PERSU A, STOENOIU MS, MESSIAEN T, et al: Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 11:229-241, 2002
35. KIM K, DRUMMOND I, IBRAGHIMOV-BESKROVNAYA O, et al: Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736, 2000
36. WALKER D, CONSUGAR M, SLEZAK J, et al: The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1. Am J Kidney Dis 41:90-94, 2003
37. WOO DD, MIAO SY, PELAYO J, WOOLF A: Taxol inhibits progression of congenital polycystic kidney disease. Nature 368:750-753, 1994